Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoRPHCF 89 ROC (Joel Greenblatt) % is 21.74% as of Mar. 2026, which is 31% below its 10-year median of 31.70. GuruFocus rates RPHCF with a GF Score™ of 89/100 and a GF Value™ of $21.04. The stock has 2 warning signs investors should review. Among 1,980 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 80.96% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Rohto Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 21.74%.
The historical rank and industry rank for Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
RPHCF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.59 Med: 31.7 Max: 39.19
Current: 32.01
During the past 13 years, Rohto Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 39.19%. The lowest was 20.59%. And the median was 31.70%.
RPHCF's ROC (Joel Greenblatt) % is ranked better than 80.96% of 1980
companies
in the Consumer Packaged Goods industry
Industry Median: 11.99
vs RPHCF: 32.01
Rohto Pharmaceutical Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.80% per year.
Rohto Pharmaceutical Co (OTCPK:RPHCF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Rohto Pharmaceutical Co ROC (Joel Greenblatt) % Related Terms
Rohto Pharmaceutical Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co ROC (Joel Greenblatt) % Chart
RPHCF vs PG, CL, KVUE: ROC (Joel Greenblatt) % Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co ROC (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Rohto Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 21.74% mean?
Rohto Pharmaceutical Co (RPHCF) has a ROC (Joel Greenblatt) % of 21.74% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Rohto Pharmaceutical Co and its competitors. This is 31% below median its historical median of 31.70. Over the past decade, Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 20.59 to 39.19. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #377 out of 1980 companies in the Consumer Packaged Goods industry, placing it in the top 19%.
Is Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Rohto Pharmaceutical Co's current ROC (Joel Greenblatt) % of 21.74% is 31% below median its 10-year median of 31.70. Over the past 10 years, this metric has ranged from a low of 20.59 to a high of 39.19. The Consumer Packaged Goods industry median ROC (Joel Greenblatt) % is 11.99. Rohto Pharmaceutical Co's value of 21.74% is 81.3% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #377 out of 1980 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Rohto Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's ROC (Joel Greenblatt) % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #377 out of 1980 companies for ROC (Joel Greenblatt) %. This places Rohto Pharmaceutical Co in the top 19% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.99. Rohto Pharmaceutical Co's value of 21.74% is 81.3% above this benchmark. Historically, Rohto Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 20.59 to 39.19 over the past decade. While the company's 10-year median is 31.70 vs. the industry median of 11.99, Rohto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median ROC (Joel Greenblatt) % among Consumer Packaged Goods companies is 11.99, based on 1,980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current ROC (Joel Greenblatt) % of 21.74% is 81.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median ROC (Joel Greenblatt) % is 11.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current ROC (Joel Greenblatt) % is 21.74%, which is 31% below median its own 10-year median of 31.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current ROC (Joel Greenblatt) % of 21.74%. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 21.74%, which is 31% below median its 10-year median of 31.70 and 81.3% above the Consumer Packaged Goods industry median of 11.99. Rohto Pharmaceutical Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current ROC (Joel Greenblatt) % is 21.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.
Key valuation signals for RPHCF:
ROC (Joel Greenblatt) %: 21.74% (31% below median its 10-year median of 31.70)
GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
Industry Position: 81.3% above the Consumer Packaged Goods median (#377 of 1980)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
89GF Score
Get the complete analysis for RPHCF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
